New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 23, 2014
09:25 EDTSNTI, SNTI, SRNE, SRNE, SPEX, SPEX, CDXC, CDXC, CBMX, CBMX, SSET, SSET, OPK, OPK, CGIX, CGIXRedChip Companies to hold a virtual conference
RedChip Emerging Growth Showcase is being held on January 22-23 with webcasted presentations to begin on January 23 at 9:30 am. Webcast Link
Check below for free stories on OPK;CGIX;SNTI;SRNE;SPEX;CDXC;CBMX;SSET the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 11, 2014
09:03 EDTOPKOPKO announces publication of MOD-4023 Phase 2 dose finding study
OPKO Health announced that the abstract “Top Line Results of Once-Weekly, CTP-Modified Human Growth Hormone: Phase 2 Dose Finding Study in Children with Growth Hormone Deficiency" has been selected for late breaking oral presentation at the 53rd Annual Meeting of the European Society of Paediatric Endocrinology on September 20. OPKO will present six month efficacy, safety, pharmacokinetic and pharmacodynamics data from the company's advanced phase 2 trial for its long acting human growth hormone hGH-CTP, or MOD-4023, in growth hormone deficient pediatric subjects. In addition, OPKO’s posters to be presented during the conference have been recognized for outstanding advancement by ESPE and will introduce additional data, as well as analytical characteristics of hGH-CTP in preparation for the planned pediatric phase 3 study. The data from this study supported once-weekly dosing for hGH-CTP and also enabled the selection of an appropriate dose to demonstrate non-inferiority compared to daily hGH in the upcoming phase 3 study. hGH-CTP demonstrated a good safety and tolerability profile in this ongoing study.
September 9, 2014
08:15 EDTSNTISenesco Technologies to change name to Sevion Therapeutics
Senesco Technologies announced a corporate rebranding under which the company will change its name to Sevion Therapeutics, Inc. The company will continue to trade as SNTI until a new ticker symbol is obtained. The rebranding and new corporate identity are first steps in fulfilling the company’s goal of becoming a preeminent, next-generation biologics company with best- and first-in-class product candidates and technologies.
September 8, 2014
12:22 EDTOPKOPKO reports licensee TESARO submits NDA for Rolapitant
Subscribe for More Information
08:13 EDTCBMXCombiMatrix announces payor contract with Blue Cross Blue Shield of Illinois
Subscribe for More Information
September 2, 2014
08:32 EDTCGIXCancer Genetics IVD for cervical cancer receives CE Mark
Cancer Genetics announced that their proprietary DNA-probe based test for cervical cancer, or FHACT, has received the CE Marking. The CE marking indicates the test's compliance with European Union product safety legislation and allows FHACT to be sold freely within the European Economic Area, or EEA, which includes the 28 member states of the EU as well as the European Free Trade Association. Cancer Genetics' proprietary FHACT test, which can identify irreversible genomic changes associated with progression to cancer, adds predictive value to this screening protocol. In addition to identifying those women most at risk for cervical disease, it can help reduce unnecessary, invasive testing and over-treatment in women who do not show the genomic abnormalities associated with disease progression.
06:03 EDTSPEXSpherix issued three new patents by USPTO
Spherix announced that the United States Patent & Trademark Office, or USPTO, issued three patents to the company in the month of August that are part of a standard essential family of patents.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use